, Volume 77, Issue 3, pp 285–301 | Cite as

Pharmacological Management of Chronic Pelvic Pain in Women

  • Erin T. CareyEmail author
  • Sara R. Till
  • Sawsan As-Sanie
Review Article


Chronic pelvic pain (CPP) is a multifaceted condition that often has both peripheral and central generators of pain. An understanding of neurobiology and neuropsychology of CPP should guide management. Successful treatment of CPP is typically multimodal, and pharmacologic treatment strategies include analgesics, hormonal suppression, anesthetics, antidepressants, membrane stabilizers, and anxiolytics. Evidence for these and other emerging pharmacologic therapies is presented in this article.


Endometriosis Pelvic Floor Fibromyalgia Pelvic Floor Muscle Chronic Pelvic Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Conflict of interest

Erin T. Carey has appeared as an expert witness (plaintiff mesh litigation); Sawsan As-Sanie is a consultant for Myriad Genetics and Daiichi Sankyo; Sara R. Till has no conflicts of interest to declare.


The authors report no external funding.


  1. 1.
    Howard FM. ACOG Practice Bulletin No. 51. Chronic pelvic pain. Obstet Gynecol. 2004;103:589–605.CrossRefGoogle Scholar
  2. 2.
    Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87:321–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Gelbaya TA, El-Halwagy HE. Focus on primary care: chronic pelvic pain in women. Obstet Gynecol Surv. 2001;56:757–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Broder MS, Kanouse DE, Mittman BS, Bernstein SJ. The appropriateness of recommendations for hysterectomy. Obstet Gynecol. 2000;95:199–205.PubMedGoogle Scholar
  5. 5.
    Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM, Marchbanks PA. Inpatient hysterectomy surveillance in the United States, 2000–2004. Am J Obstet Gynecol. 2008;198(34):e1–7.Google Scholar
  6. 6.
    Howard FM. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. Obstet Gynecol Surv. 1993;48:357–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Howard FM. Surgical treatment of endometriosis. Obstet Gynecol Clin N Am. 2011;38:677–86.CrossRefGoogle Scholar
  8. 8.
    Howard FM. Chronic pelvic pain. Obstet Gynecol. 2003;101:594–611.PubMedGoogle Scholar
  9. 9.
    As-Sanie S, Clevenger LA, Geisser ME, Williams DA, Roth RS. History of abuse and its relationship to pain experience and depression in women with chronic pelvic pain. Am J Obstet Gynecol. 2014;210(317):e1–8.Google Scholar
  10. 10.
    Anderson RU, Orenberg EK, Chan CA, Morey A, Flores V. Psychometric profiles and hypothalamic-pituitary-adrenal axis function in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2008;179:956–60.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Benzon H, Raja SN, Fishman SE, Liu S, Cohen SP. Essentials of pain medicine. Elsevier Health Sciences. 2011;5-6, 201-204.Google Scholar
  13. 13.
    Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain. 2009;10:777–91.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain. 2009;10:1113–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril. 1996;65:299–304.PubMedCrossRefGoogle Scholar
  18. 18.
    Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with chronic pelvic pain and endometriosis. Hum Reprod Update. 2014;20:737–47.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    As-Sanie S, Kim J, Schmidt-Wilcke T, Sundgren PC, Clauw DJ, Napadow V, et al. Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. J Pain. 2016;17:1–13.PubMedCrossRefGoogle Scholar
  20. 20.
    As-Sanie S, Harris RE, Napadow V, Kim J, Neshewat G, Kairys A, et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain. 2012;153:1006–14.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    As-Sanie S, Harris RE, Harte SE, Tu FF, Neshewat G, Clauw DJ. Increased pressure pain sensitivity in women with chronic pelvic pain. Obstet Gynecol. 2013;122:1047–55.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Malykhina AP. Neural mechanisms of pelvic organ cross-sensitization. Neuroscience. 2007;149:660–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Balasch J, Creus M, Fábregues F, Carmona F, Ordi J, Martinez-Román S, et al. Visible and non-visible endometriosis at laparoscopy in fertile and infertile women and in patients with chronic pelvic pain: a prospective study. Hum Reprod. 1996;11:387–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Porpora MG, Koninckx PR, Piazze J, Natili M, Colagrande S, Cosmi EV. Correlation between endometriosis and pelvic pain. J Am Assoc Gynecol Laparosc. 1999;6:429–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Alappattu MJ, Bishop MD. Psychological factors in chronic pelvic pain in women: relevance and application of the fear-avoidance model of pain. Phys Ther. 2011;91:1542–50.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Kwon JK, Chang IH. Pain, catastrophizing, and depression in chronic prostatitis/chronic pelvic pain syndrome. Int Neurourol J. 2013;17:48–58.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Meltzer-Brody S, Leserman J. Psychiatric comorbidity in women with chronic pelvic pain. CNS Spectr. 2011;16:29–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Koutantji M, Pearce SA, Oakley DA. The relationship between gender and family history of pain with current pain experience and awareness of pain in others. Pain. 1998;77:25–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Angst J, Gamma A, Gastpar M, Lépine J-P, Mendlewicz J, Tylee A. Gender differences in depression. Eur Arch Psychiatry Clin Neurosci. 2002;252:201–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Peters ML. Emotional and cognitive influences on pain experience. Mod Trends Pharmacopsychiatr. 2015;30:138–52.CrossRefGoogle Scholar
  31. 31.
    Phillips ML, Gregory LJ, Cullen S, et al. The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation. Brain. 2003;126:669–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Campbell LC, Clauw DJ, Keefe FJ. Persistent pain and depression: a biopsychosocial perspective. Biol Psychiatry. 2003;54:399–409.PubMedCrossRefGoogle Scholar
  33. 33.
    Williams DA. The importance of psychological assessment in chronic pain. Curr Opin Urol. 2013;23:554–9.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–45.PubMedCrossRefGoogle Scholar
  35. 35.
    Read J, Cartwright C, Gibson K, Shiels C, Haslam N. Beliefs of people taking antidepressants about causes of depression and reasons for increased prescribing rates. J Affect Disord. 2014;168:236–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76:287–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Romão APMS, Gorayeb R, Romão GS, Poli-Neto OB, dos Reis FJC, Rosa-e-Silva JC, et al. High levels of anxiety and depression have a negative effect on quality of life of women with chronic pelvic pain. Int J Clin Pract. 2009;63:707–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Miller-Matero LR, Saulino C, Clark S, Bugenski M, Eshelman A, Eisenstein D. When treating the pain is not enough: a multidisciplinary approach for chronic pelvic pain. Arch Womens Ment Health. 2016;19:349–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, et al. The community prevalence of chronic pelvic pain in women and associated illness behaviour. Br J Gen Pract. 2001;51:541–7.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Mifflin K, Benson C, Kerr B, Aricioglu F, Cetin M, Dursun S, et al. Involvement of neuroactive steroids in pain, depression and anxiety. Mod Trends Pharmacopsychiatr. 2015;30:94–102.CrossRefGoogle Scholar
  41. 41.
    Merkes M. Mindfulness-based stress reduction for people with chronic diseases. Aust J Prim Health. 2010;16:200–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Kasckow JW, Baker D, Geracioti TD Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides. 2001;22:845–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Lariviere WR, Fiorenzani P, Ceccarelli I, Massafra C, Sorda G, Di Canio C, et al. Central CRH administration changes formalin pain responses in male and female rats. Brain Res. 2011;1383:128–34.PubMedCrossRefGoogle Scholar
  44. 44.
    Fukudo S. Stress and visceral pain: focusing on irritable bowel syndrome. Pain. 2013;154(Suppl 1):S63–70.PubMedCrossRefGoogle Scholar
  45. 45.
    McCall JG, Al-Hasani R, Siuda ER, Hong DY, Norris AJ, Ford CP, et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron. 2015;87:605–20.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Wingenfeld K, Hellhammer DH, Schmidt I, Wagner D, Meinlschmidt G, Heim C. HPA axis reactivity in chronic pelvic pain: association with depression. J Psychosom Obstet Gynaecol. 2009;30:282–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Quiñones M, Urrutia R, Torres-Reverón A, Vincent K, Flores I. Anxiety, coping skills and hypothalamus-pituitary-adrenal (HPA) axis in patients with endometriosis. J Reprod Biol Health. 2015. doi: 10.7243/2054-0841-3-2 (Epub 11 Jun 2015).
  48. 48.
    Pierce AN, Christianson JA. Stress and chronic pelvic pain. Prog Mol Biol Transl Sci. 2015;131:509–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Paras ML, Murad MH, Chen LP, Goranson EN, Sattler AL, Colbenson KM, et al. Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. JAMA. 2009;302:550–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Pennebaker JW, Susman JR. Disclosure of traumas and psychosomatic processes. Soc Sci Med. 1988;26:327–32.PubMedCrossRefGoogle Scholar
  51. 51.
    Cosic A, Ferhatovic L, Banozic A, Kraljevic S, Maric A, Sapunar D, et al. Pain catastrophizing changes during the menstrual cycle. Psychol Health Med. 2013;18:735–41.PubMedCrossRefGoogle Scholar
  52. 52.
    Turner JA, Jensen MP, Romano JM. Do beliefs, coping, and catastrophizing independently predict functioning in patients with chronic pain? Pain. 2000;85:115–25.PubMedCrossRefGoogle Scholar
  53. 53.
    Keefe FJ, Brown GK, Wallston KA, Caldwell DS. Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy. Pain. 1989;37:51–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Davis MC, Zautra AJ, Wolf LD, Tennen H, Yeung EW. Mindfulness and cognitive–behavioral interventions for chronic pain: differential effects on daily pain reactivity and stress reactivity. J Consult Clin Psychol. 2015;83:24.PubMedCrossRefGoogle Scholar
  55. 55.
    Flink IK, Boersma K, Linton SJ. Changes in catastrophizing and depressed mood during and after early cognitive behaviorally oriented interventions for pain. Cogn Behav Ther. 2014;43:332–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Ludäscher P, von Kalckreuth C, Parzer P, Kaess M, Resch F, Bohus M, et al. Pain perception in female adolescents with borderline personality disorder. Eur Child Adolesc Psychiatry. 2015;24:351–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Schmahl C, Greffrath W, Baumgärtner U, Schlereth T, Magerl W, Philipsen A, et al. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain. 2004;110:470–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;(2):CD001751.Google Scholar
  59. 59.
    Jarrell JF, Vilos GA, Allaire C, et al. Consensus guidelines for the management of chronic pelvic pain. J Obstet Gynaecol Can. 2005;27:781–826.PubMedCrossRefGoogle Scholar
  60. 60.
    Jabbour HN, Kelly RW, Fraser HM, Critchley HOD. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.PubMedCrossRefGoogle Scholar
  61. 61.
    García Rodríguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum. 1997;26:16–20.PubMedCrossRefGoogle Scholar
  62. 62.
    Makin AJ, Williams R. Acetaminophen-induced hepatotoxicity: predisposing factors and treatments. Adv Intern Med. 1997;42:453–83.PubMedGoogle Scholar
  63. 63.
    Baranowski AP, Lee J, Price C, Hughes J. Pelvic pain: a pathway for care developed for both men and women by the British Pain Society. Br J Anaesth. 2014;112:452–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD Jr, et al. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. ACS Chem Neurosci. 2013;4:1256–66.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30:138–40.CrossRefGoogle Scholar
  66. 66.
    Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118:691–705.PubMedCrossRefGoogle Scholar
  67. 67.
    Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91:16–24.PubMedCrossRefGoogle Scholar
  68. 68.
    Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;(4):CD001297.Google Scholar
  69. 69.
    The Cochrane Collaboration. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010; 13-18.Google Scholar
  70. 70.
    Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2007;(4):CD000068.Google Scholar
  71. 71.
    Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987;1:13–23.PubMedCrossRefGoogle Scholar
  72. 72.
    Lavelle ED, Lavelle W, Smith HS. Myofascial trigger points. Anesthesiol Clin. 2007;25:841–51, vii–iii.Google Scholar
  73. 73.
    Srinivasan R, Greenbaum DS. Chronic abdominal wall pain: a frequently overlooked problem. Am J Gastroenterol. 2002;97:824–30.PubMedGoogle Scholar
  74. 74.
    Labat JJ, Riant T, Lassaux A, Rioult B, Rabischong B, Khalfallah M, et al. Adding corticosteroids to the pudendal nerve block for pudendal neuralgia: a randomised, double-blind, controlled trial. BJOG. 2017;124(2):251–60.PubMedCrossRefGoogle Scholar
  75. 75.
    Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26:59–62.PubMedCrossRefGoogle Scholar
  76. 76.
    Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S, Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007;(3):CD000319.Google Scholar
  77. 77.
    Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med. 2009;10:54–69.PubMedCrossRefGoogle Scholar
  78. 78.
    Hameroff SR, Crago BR, Blitt CD, Womble J, Kanel J. Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anesth Analg. 1981;60:752–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Vancaillie T, Eggermont J, Armstrong G, Jarvis S, Liu J, Beg N. Response to pudendal nerve block in women with pudendal neuralgia. Pain Med. 2012;13:596–603.PubMedCrossRefGoogle Scholar
  80. 80.
    Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Am J Obstet Gynecol. 2008;198(41):e1–5.Google Scholar
  81. 81.
    Zoorob D, South M, Karram M, Sroga J, Maxwell R, Shah A, et al. A pilot randomized trial of levator injections versus physical therapy for treatment of pelvic floor myalgia and sexual pain. Int Urogynecol J. 2015;26:845–52.PubMedCrossRefGoogle Scholar
  82. 82.
    Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther. 2009;31:705–20.PubMedCrossRefGoogle Scholar
  83. 83.
    Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102:84–7.PubMedGoogle Scholar
  84. 84.
    Foster DC, Kotok MB, Huang L-S, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116:583–93.PubMedCrossRefGoogle Scholar
  85. 85.
    Tamano R, Ishida M, Asaki T, Hasegawa M, Shinohara S. Effect of spinal monoaminergic neuronal system dysfunction on pain threshold in rats, and the analgesic effect of serotonin and norepinephrine reuptake inhibitors. Neurosci Lett. 2016;615:78–82.PubMedCrossRefGoogle Scholar
  86. 86.
    Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(12):CD008242.Google Scholar
  87. 87.
    An update on the drug treatment of neuropathic pain. Part 1: antidepressants. Drug Ther Bull. 2012;50:114–117.Google Scholar
  88. 88.
    Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med. 1996;156:1047–52.PubMedCrossRefGoogle Scholar
  89. 89.
    Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A, et al. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr. 2005;117:761–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51:9–13.PubMedCrossRefGoogle Scholar
  91. 91.
    Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38:2653–63.PubMedCrossRefGoogle Scholar
  92. 92.
    Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007;8(Suppl 2):S63–74.PubMedCrossRefGoogle Scholar
  93. 93.
    Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975–85.PubMedGoogle Scholar
  94. 94.
    Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, et al. Off-label trazodone prescription: evidence, benefits and risks. Curr Pharm Des. 2015;21:3343–51.PubMedCrossRefGoogle Scholar
  95. 95.
    Lewis SC, Bhattacharya S, Wu O, Vincent K, Jack SA, Critchley HOD, et al. Gabapentin for the management of chronic pelvic pain in women (GaPP1): a pilot randomised controlled trial. PLoS One. 2016;11:e0153037.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin–a meta-analysis of randomized controlled trials. Pain. 2009;145:69–81.PubMedCrossRefGoogle Scholar
  97. 97.
    Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4):CD007938.Google Scholar
  98. 98.
    Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics. 2009;6:663–78.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Muehlbacher M, Nickel MK, Kettler C, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2006;22:526–31.PubMedCrossRefGoogle Scholar
  100. 100.
    Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, Fariello JY, Whitmore KE. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010;21:895–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Carrico DJ, Peters KM. Vaginal diazepam use with urogenital pain/pelvic floor dysfunction: serum diazepam levels and efficacy data. Urol Nurs. 2011;31(279–84):299.Google Scholar
  102. 102.
    Poli-Neto OB, Filho AA, Rosa e Silva JC, Barbosa Hde F, Candido Dos Reis FJ, Nogueira AA. Increased capsaicin receptor TRPV1 in the peritoneum of women with chronic pelvic pain. Clin J Pain. 2009;25:218–22.PubMedCrossRefGoogle Scholar
  103. 103.
    Rocha MG, e Silva JCR, Ribeiro da Silva A, Candido Dos Reis FJ, Nogueira AA, Poli-Neto OB. TRPV1 expression on peritoneal endometriosis foci is associated with chronic pelvic pain. Reprod Sci. 2011;18:511–5.PubMedCrossRefGoogle Scholar
  104. 104.
    Turini D, Beneforti P, Spinelli M, Malagutti S, Lazzeri M. Heat/burning sensation induced by topical application of capsaicin on perineal cutaneous area: new approach in diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome? Urology. 2006;67:910–3.PubMedCrossRefGoogle Scholar
  105. 105.
    Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol. 2011;2:54.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53:3–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Kim D-W, Lee S-K, Ahnn J. Botulinum toxin as a pain killer: players and actions in antinociception. Toxins. 2015;7:2435–53.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18:S125–32.PubMedCrossRefGoogle Scholar
  109. 109.
    Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44:46–50.PubMedCrossRefGoogle Scholar
  110. 110.
    Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003;29:519–22 (discussion 522).Google Scholar
  111. 111.
    Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108:915–23.PubMedCrossRefGoogle Scholar
  112. 112.
    Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O’Hare P 3rd, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographical guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg. 2015;21:277–82.PubMedCrossRefGoogle Scholar
  113. 113.
    Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;(5):CD009923.Google Scholar
  114. 114.
    Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33:451–9.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529–38.PubMedCrossRefGoogle Scholar
  116. 116.
    Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328–35.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Walczak JS, Price TJ, Cervero F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience. 2009;159:1154–63.PubMedCrossRefGoogle Scholar
  118. 118.
    Mukerji G, Yiangou Y, Agarwal SK, Anand P. Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology. 2010;75(1514):e15–20.Google Scholar
  119. 119.
    Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Walitt B, Klose P, Fitzcharles M-A, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;(7):CD011694.Google Scholar
  121. 121.
    Dutta A, McKie S, Deakin JFW. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015;225:1–13.PubMedCrossRefGoogle Scholar
  122. 122.
    McRoberts JA, Coutinho SV, Marvizón JC, et al. Role of peripheral N-methyl-d-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology. 2001;120:1737–48.PubMedCrossRefGoogle Scholar
  123. 123.
    Serra G, Demontis F, Serra F, De Chiara L, Spoto A, Girardi P, et al. Memantine: new prospective in bipolar disorder treatment. World J Psychiatry. 2014;4:80–90.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Krystal JH. N-Methyl-d-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Arch Gen Psychiatry. 2010;67:1110–1.PubMedCrossRefGoogle Scholar
  125. 125.
    John JP, Lukose A, Manjunath S. Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. Pharmacopsychiatry. 2014;47:202–9.PubMedCrossRefGoogle Scholar
  126. 126.
    Morel V, Etienne M, Wattiez A-S, Dupuis A, Privat A-M, Chalus M, et al. Memantine, a promising drug for the prevention of neuropathic pain in rat. Eur J Pharmacol. 2013;721:382–90.PubMedCrossRefGoogle Scholar
  127. 127.
    Nickel JC, Atkinson G, Krieger JN, Mills IW, Pontari M, Shoskes DA, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80:1105–10.PubMedCrossRefGoogle Scholar
  128. 128.
    Nickel JC, Mills IW, Crook TJ, Jorga A, Smith MD, Atkinson G, et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with neurological associated somatic syndromes. J Urol. 2016;195:942–8.PubMedCrossRefGoogle Scholar
  129. 129.
    Barcena de Arellano ML, Arnold J, Vercellino F, Chiantera V, Schneider A, Mechsner S. Overexpression of nerve growth factor in peritoneal fluid from women with endometriosis may promote neurite outgrowth in endometriotic lesions. Fertil Steril. 2011;95:1123–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Kajitani T, Maruyama T, Asada H, Uchida H, Oda H, Uchida S, et al. Possible involvement of nerve growth factor in dysmenorrhea and dyspareunia associated with endometriosis. Endocr J. 2013;60:1155–64.PubMedCrossRefGoogle Scholar
  131. 131.
    Chen W, Ye D-Y, Han D-J, Fu G-Q, Zeng X, Lin W, et al. Elevated level of nerve growth factor in the bladder pain syndrome/interstitial cystitis: a meta-analysis. Springerplus. 2016;5:1072.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Tommola P, Unkila-Kallio L, Paetau A, Meri S, Kalso E, Paavonen J. Immune activation enhances epithelial nerve growth in provoked vestibulodynia. Am J Obstet Gynecol. 2016;215(6):768.e1–768.e8.Google Scholar
  133. 133.
    Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68:382–91.PubMedCrossRefGoogle Scholar
  134. 134.
    Badawy SZA, Brown S, Kaufman L, Wojtowycz MA. Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture. Eur J Obstet Gynecol Reprod Biol. 2015;188:45–50.PubMedCrossRefGoogle Scholar
  135. 135.
    Abushahin F, Goldman KN, Barbieri E, Milad M, Rademaker A, Bulun SE. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 2011;96:939–42.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Almassinokiani F, Almasi A, Akbari P, Saberifard M. Effect of letrozole on endometriosis-related pelvic pain. Med J Islam Repub Iran. 2014;28:107.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19:160–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. 2008;115:818–22.PubMedCrossRefGoogle Scholar
  140. 140.
    Diamond MP, Carr B, Dmowski WP, Koltun W, O’Brien C, Jiang P, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21:363–71.PubMedCrossRefGoogle Scholar
  141. 141.
    Goldfinger C, Pukall CF, Thibault-Gagnon S, McLean L, Chamberlain S. Effectiveness of cognitive-behavioral therapy and physical therapy for provoked vestibulodynia: a randomized pilot study. J Sex Med. 2016;13:88–94.PubMedCrossRefGoogle Scholar
  142. 142.
    Fitzgerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2013;189:S75–85.PubMedCrossRefGoogle Scholar
  143. 143.
    FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. II: treatment of the patient with the short pelvic floor. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:269–75 (discussion 275).Google Scholar
  144. 144.
    Liu L, Huang Q-M, Liu Q-G, Ye G, Bo C-Z, Chen M-J, et al. Effectiveness of dry needling for myofascial trigger points associated with neck and shoulder pain: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2015;96:944–55.PubMedCrossRefGoogle Scholar
  145. 145.
    Cerezo-Téllez E, Torres-Lacomba M, Fuentes-Gallardo I, Perez-Muñoz M, Mayoral-Del-Moral O, Lluch-Girbés E, et al. Effectiveness of dry needling for chronic nonspecific neck pain: a randomized, single-blinded, clinical trial. Pain. 2016;157:1905–17.PubMedCrossRefGoogle Scholar
  146. 146.
    Williams DA, Cary MA, Groner KH, Chaplin W, Glazer LJ, Rodriguez AM, et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol. 2002;29:1280–6.PubMedGoogle Scholar
  147. 147.
    Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced management of fibromyalgia: a randomized controlled trial. Pain. 2010;151:694–702.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Bernardy K, Klose P, Busch AJ, Choy EHS, Häuser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;(9):CD009796.Google Scholar
  149. 149.
    van Koulil S, van Lankveld W, Kraaimaat FW, et al. Tailored cognitive-behavioral therapy and exercise training for high-risk patients with fibromyalgia. Arthritis Care Res. 2010;62:1377–85.CrossRefGoogle Scholar
  150. 150.
    Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151:280–95.PubMedCrossRefGoogle Scholar
  151. 151.
    Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom. 2007;76:226–33.PubMedCrossRefGoogle Scholar
  152. 152.
    Monteiro ÉS, de Carvalho LBC, Fukujima MM, Lora MI, do Prado GF. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology. 2014;84:509–14.PubMedCrossRefGoogle Scholar
  153. 153.
    Wibisono E, Rahardjo HE. Effectiveness of short term percutaneous tibial nerve stimulation for non-neurogenic overactive bladder syndrome in adults: a meta-analysis. Acta Med Indones. 2015;47:188–200.PubMedGoogle Scholar
  154. 154.
    Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev. 2002;(1):CD002123.Google Scholar
  155. 155.
    Gozani SN. Fixed-site high-frequency transcutaneous electrical nerve stimulation for treatment of chronic low back and lower extremity pain. J Pain Res. 2016;9:469–79.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Sierakowski A, Jing SS, Poel J, Elliot D. Transcutaneous peripheral nerve stimulation for the treatment of neuropathic pain in the upper limb. J Hand Surg Asian Pac. 2016;21:37–43.CrossRefGoogle Scholar
  157. 157.
    Iodice P, Lessiani G, Franzone G, Pezzulo G. Efficacy of pulsed low-intensity electric neuromuscular stimulation in reducing pain and disability in patients with myofascial syndrome. J Biol Regul Homeost Agents. 2016;30:615–20.PubMedGoogle Scholar
  158. 158.
    Upton GA, Tinley P, Al-Aubaidy H, Crawford R. The influence of transcutaneous electrical nerve stimulation parameters on the level of pain perceived by participants with painful diabetic neuropathy: a crossover study. Diabetes Metab Syndr. 2016. doi: 10.1016/j.dsx.2016.08.016 (Epub 23 Aug 2016).
  159. 159.
    Ellrich J, Lamp S. Peripheral nerve stimulation inhibits nociceptive processing: an electrophysiological study in healthy volunteers. Neuromodulation. 2005;8:225–32.PubMedCrossRefGoogle Scholar
  160. 160.
    Kocyigit F, Akalin E, Gezer NS, Orbay O, Kocyigit A, Ada E. Functional magnetic resonance imaging of the effects of low-frequency transcutaneous electrical nerve stimulation on central pain modulation: a double-blind, placebo-controlled trial. Clin J Pain. 2012;28:581–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Valovska A, Peccora CD, Philip CN, Kaye AD, Urman RD. Sacral neuromodulation as a treatment for pudendal neuralgia. Pain Physician. 2014;17:E645–50.PubMedGoogle Scholar
  162. 162.
    Peters KM, Killinger KA, Jaeger C, Chen C. Pilot study exploring chronic pudendal neuromodulation as a treatment option for pain associated with pudendal neuralgia. Low Urin Tract Symptoms. 2015;7:138–42.PubMedCrossRefGoogle Scholar
  163. 163.
    Fenton BW, Palmieri PA, Boggio P, Fanning J, Fregni F. A preliminary study of transcranial direct current stimulation for the treatment of refractory chronic pelvic pain. Brain Stimul. 2009;2:103–7.PubMedCrossRefGoogle Scholar
  164. 164.
    Simis M, Reidler JS, Duarte Macea D, Moreno Duarte I, Wang X, Lenkinski R, et al. Investigation of central nervous system dysfunction in chronic pelvic pain using magnetic resonance spectroscopy and noninvasive brain stimulation. Pain Pract. 2015;15:423–32.PubMedCrossRefGoogle Scholar
  165. 165.
    Marziali M, Venza M, Lazzaro S, Lazzaro A, Micossi C, Stolfi VM. Gluten-free diet: a new strategy for management of painful endometriosis related symptoms? Minerva Chir. 2012;67:499–504.PubMedGoogle Scholar
  166. 166.
    Slim M, Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Molina-Barea R, Rodriguez-Lopez CM, et al. The effects of a gluten-free diet versus a hypocaloric diet among patients with fibromyalgia experiencing gluten sensitivity-like symptoms: a pilot, open-label randomized clinical trial. J Clin Gastroenterol. 2016. doi: 10.1097/MCG.0000000000000651 (Epub 19 Aug 2016).
  167. 167.
    Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;(3):CD002124.Google Scholar
  168. 168.
    Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients. Female Pelvic Med Reconstr Surg. 2011;17:36–9.PubMedCrossRefGoogle Scholar
  169. 169.
    Elli L, Tomba C, Branchi F, et al. Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge. Nutrients. 2016;8:84.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Gearry R, Skidmore P, O’Brien L, Wilkinson T, Nanayakkara W. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131–42.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Erin T. Carey
    • 1
    Email author
  • Sara R. Till
    • 2
  • Sawsan As-Sanie
    • 2
  1. 1.Department of Obstetrics and GynecologyUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of Obstetrics and GynecologyUniversity of MichiganAnn ArborUSA

Personalised recommendations